

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

ALLERGAN, INC.
Patent Owner

Case IPR2016-01130
Patent 8,633,162

**PATENT OWNER ALLERGAN, INC.'S
MANDATORY NOTICES**

**PATENT OWNER'S MANDATORY NOTICES
UNDER 37 C.F.R. § 42.8**

Pursuant to 37 C.F.R. § 42.8, the patent owner, Allergan, Inc. ("Patent Owner"), hereby submits the following Mandatory Notices in response to the Petition for *Inter Partes* Review of U.S. Patent No. 8,633,162.

1. Real Party-In-Interest under 37 CFR § 42.8(b)(1)

Allergan, Inc. is the Patent Owner and the Real Party-In-Interest in this proceeding.

2. Related Matters under 37 CFR § 42.8(b)(2)

The following judicial or administrative matters may affect or be affected by a decision in this proceeding: *Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., et al.*, No. 2:15-cv-01455 (D. Texas); *Allergan, Inc., v. Innopharma, Inc. and Pfizer, Inc.*, No. 2:15-cv-1504 (D. Texas); and *Allergan, Inc. v. Famy Care, Ltd.*, No. 2:16-cv-0401 (D. Texas).

The following petitions for *inter partes review* are related to U.S. Patent No. 8,633,162: IPR2015-01278 (terminated before institution), U.S. Patent Nos. 8,648,048 (IPR2015-01284, terminated before institution), 8,642,556 (IPR2015-01286, terminated before institution), 8,629,111 (IPR2015-01282, terminated before institution), and 8,685,930 (IPR2015-01283, terminated before institution).

The following petitions for *inter partes review* are pending for related U.S. Patent Nos. 8,685,930 (IPR2016-01127), 8,629,111 (IPR2016-01128 and IPR2016-01232), 8,642,556 (IPR2016-01129), 8,648,048 (IPR2016-01131), and 9,248,191 (IPR2016-01132).

The following patents and pending patent applications are related to U.S. Patent No. 8,633,162: U.S. Application No. 15/011,159, filed January 29, 2016, claims the benefit of U.S. Application No. 14/222,478 (9,248,191), which is a continuation, via U.S. Application Nos. 13/961,828 and 11/897,177, of U.S. Application No. 10/927,857.

3. Lead and Back-Up Counsel, under 37 CFR § 42.8(b)(3)

The Patent Owner designates the following lead and back-up counsel:

LEAD COUNSEL	BACK-UP COUNSEL
Dorothy P. Whelan, Reg. No. 33,814 3200 RBC Plaza 60 South Sixth Street Minneapolis, MN 55402 Tel: (612) 337-2509 Email: IPR13351-0008IP4@fr.com Fax: (612) 288-9696	Michael Kane, Reg. No. 39,722 3200 RBC Plaza 60 South Sixth Street Minneapolis, MN 55402 Tel: (612) 337-2502 Email: PTABInbound@fr.com Fax: (612) 288-9696

4. Service Information under 37 CFR § 42.8(b)(4)(i) et seq.

Please address all correspondence and service to both counsel as listed above. Patent Owner consents to service by email at IPR13351-0008IP4@fr.com (ref.: Docket No. IPR13351-0008IP4).

Respectfully submitted,

Date: June 27, 2016/

/Dorothy P. Whelan/

Dorothy P. Whelan

Reg. No. 33,814

Customer Number 26191

Fish & Richardson P.C.

Telephone: (612) 337-2508

Facsimile: (612) 288-9696

